Genetics of cognitive dysfunction in Parkinson's disease.

Presentation and progression of cognitive symptoms in Parkinson's disease are highly variable. PD is a genetically complex disorder with multiple genetic risk factors and understanding the role that genes play in cognitive outcomes is important for patient counseling and treatment. Currently, there are seven well-described genes that increase the risk for PD, with variable levels of penetrance: SNCA, LRRK2, VPS35, PRKN, PINK1, DJ1 and GBA. In addition, large, genome-wide association studies have identified multiple loci in our DNA which increase PD risk. In this chapter, we summarize what is currently known about each of the seven strongly-associated PD genes and select PD risk variants, including PITX3, TMEM106B, SNCA Rep1, APOɛ4, COMT and MAPT H1/H1, along with their respective relationships to cognition.

• Publication year

  2022

• Venue

  Progress in Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/bs.pbr.2022.01.015PMID 35248195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations

  2021cited by this paper
• APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease

  2021cited by this paper
• Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers

  2021cited by this paper
• The Parkinson's Disease Genome‐Wide Association Study Locus Browser

  2020cited by this paper
• Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.

  2020cited by this paper
• Neuropathological findings in PINK1-associated Parkinson's disease.

  2020cited by this paper
• Cognitive and psychiatric symptoms in genetically determined Parkinson’s disease: a systematic review

  2020cited by this paper
• Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism

  2020cited by this paper
• VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology.

  2020cited by this paper
• PINK1 and Parkin: the odd couple.

  2020cited by this paper
• Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study.

  2020cited by this paper
• Comprehensive assessment of PINK1 variants in Parkinson's disease.

  2020cited by this paper
• Characterization of Recessive Parkinson Disease in a Large Multicenter Study.

  2020cited by this paper
• Characterization of Recessive Parkinson Disease in a Large Multicenter Study

  2020cited by this paper
• Long-Term Outcomes of Genetic Parkinson’s Disease

  2020cited by this paper
• GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort

  2020cited by this paper
• Genetic Risk Profiling in Parkinson’s Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways

  2020cited by this paper
• Dementia in long-term Parkinson’s disease patients: a multicentre retrospective study

  2020cited by this paper
• Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort

  2020cited by this paper
• Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.

  2020cited by this paper
• Genetic risk scores and hallucinations in patients with Parkinson disease

  2020cited by this paper
• Expanding the canvas of PRKN mutations in familial and early-onset Parkinson disease.

  2019cited by this paper
• Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.

  2019cited by this paper
• The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure

  2019cited by this paper
• Classification of GBA Variants and Their Effects in Synucleinopathies

  2019cited by this paper
• Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia

  2019cited by this paper
• Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson’s Disease

  2019cited by this paper
• A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease

  2019cited by this paper
• Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease

  2019cited by this paper
• TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia

  2019cited by this paper
• SNCA Rep1 promoter variability influences cognition in Parkinson's disease

  2019cited by this paper
• Meta-Analysis of the Effects of the Catechol-O-Methyltransferase Val158/108Met Polymorphism on Parkinson’s Disease Susceptibility and Cognitive Dysfunction

  2019cited by this paper
• Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts

  2019cited by this paper
• Progression in the LRRK2-Asssociated Parkinson Disease Population

  2018cited by this paper
• Alpha galactosidase A activity in Parkinson's disease.

  2018cited by this paper
• A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism

  2018cited by this paper
• The genetic landscape of Parkinson's disease.

  2018cited by this paper
• New Frontiers in Parkinson's Disease: From Genetics to the Clinic

  2018cited by this paper
• APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology

  2018cited by this paper
• Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease

  2018cited by this paper
• Genotype‐phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review

  2018cited by this paper
• The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease

  2018cited by this paper
• Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review

  2018cited by this paper
• Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications

  2018cited by this paper
• Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease

  2018cited by this paper
• GBA-Associated Parkinson’s Disease and Other Synucleinopathies

  2018cited by this paper
• Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature

  2017cited by this paper
• A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype.

  2017cited by this paper
• Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients

  2017cited by this paper
• Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels

  2017cited by this paper
• Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry

  2017cited by this paper
• Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease.

  2017cited by this paper
• Nonmotor Signs in Genetic Forms of Parkinson's Disease.

  2017cited by this paper
• Genetic Forms of Parkinson's Disease

  2017cited by this paper
• LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease

  2017cited by this paper
• Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers.

  2017cited by this paper
• Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review

  2017cited by this paper
• Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

  2017cited by this paper
• Variants in SNCA Gene Are Associated with Parkinson’s Disease Risk and Cognitive Symptoms in a Brazilian Sample

  2017cited by this paper
• PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study.

  2017cited by this paper
• GBA-Associated Parkinson’s Disease: Progression in a Deep Brain Stimulation Cohort

  2017cited by this paper
• DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology.

  2016cited by this paper
• High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews.

  2016cited by this paper
• Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters

  2016cited by this paper
• α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease

  2016cited by this paper
• APOE, MAPT, and COMT and Parkinson’s Disease Susceptibility and Cognitive Symptom Progression

  2016cited by this paper
• GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder

  2015cited by this paper
• Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease.

  2015cited by this paper
• Differential effects of severe vs mild GBA mutations on Parkinson disease

  2015cited by this paper
• Cognitive profile of LRRK2‐related Parkinson's disease

  2015cited by this paper
• Progressive decline of glucocerebrosidase in aging and Parkinson's disease

  2015cited by this paper
• Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.

  2015cited by this paper
• Glucocerebrosidase and Parkinson disease: Recent advances.

  2015cited by this paper
• Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

  2015cited by this paper
• Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals

  2015cited by this paper
• Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

  2015cited by this paper
• Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

  2015cited by this paper
• Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.

  2014cited by this paper
• VPS35 Parkinson’s disease phenotype resembles the sporadic disease

  2014cited by this paper
• Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.

  2014cited by this paper
• APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

  2014cited by this paper
• Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

  2014cited by this paper
• Phenotypic variability of PINK1 expression: 12 Years' clinical follow‐up of two Italian families

  2014cited by this paper
• LRRK2 parkinsonism in Tunisia and Norway: A comparative analysis of disease penetrance

  2014cited by this paper
• APOE ε4 increases risk for dementia in pure synucleinopathies.

  2013cited by this paper
• Genotype and phenotype in Parkinson's disease: Lessons in heterogeneity from deep brain stimulation

  2013cited by this paper
• A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.

  2013cited by this paper
• The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function.

  2013cited by this paper
• The many faces of alpha‐synuclein mutations

  2013cited by this paper
• Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.

  2012cited by this paper
• Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson’s disease

  2012cited by this paper
• A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants

  2012cited by this paper
• Cognitive performance of GBA mutation carriers with early-onset PD

  2012cited by this paper
• Genetic influences on cognitive decline in Parkinson's disease

  2012cited by this paper
• Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains

  2012cited by this paper
• Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers

  2012cited by this paper
• A large study reveals no association between APOE and Parkinson's disease.

  2012cited by this paper
• Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease

  2011cited by this paper
• GBA-associated PD presents with nonmotor characteristics

  2011cited by this paper
• Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy

  2011cited by this paper

• More Than Rapid Eye Movement Sleep Behavior Disorder: Sleep Differences in Parkinson’s Disease LRRK2 and GBA Genotypes

  2025cites this paper
• Radiological markers of CSF α-synuclein aggregation in Parkinson’s disease patients

  2025cites this paper
• Executive dysfunction in Parkinson's disease: From neurochemistry to circuits, genetics and neuroimaging.

  2025cites this paper
• PADG‐Pred: Exploring Ensemble Approaches for Identifying Parkinson's Disease Associated Biomarkers Using Genomic Sequences Analysis

  2025cites this paper
• Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders

  2025cites this paper
• Increased TMEM106B levels lead to lysosomal dysfunction which affects synaptic signaling and neuronal health

  2025cites this paper
• LncRNA-induced lysosomal localization of NHE1 promotes increased lysosomal pH in macrophages leading to atherosclerosis

  2025cites this paper
• Cognitive Decline in Parkinsonism: From Clinical Phenotypes to the Genetic Background

  2025cites this paper
• Mild cognitive impairment in Parkinson's disease: current view

  2024cites this paper
• Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”

  2023cites this paper
• Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis

  2023cites this paper
• Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

  2023cites this paper
• Morphological basis of Parkinson disease-associated cognitive impairment: an update

  2022cites this paper
• Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease

  2022cites this paper
• Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease

  2022cites this paper